INTRODUCTION. Gastroesophageal reflux disease (GERD) is an actual problem of practical healthcare, which is also caused by high financial costs. The latter need a reasoned correction. THE AIM is a pharmacoeconomic analysis of GERD maintenance therapy based on clinical recommendations. MATERIALS AND METHODS. 104 GERD patients were selected from 2,130 respondents. They performed ABC/VEN and frequency analysis of drug therapy: alginates; proton pump inhibitors (PPIs), antacids; H2-histamine receptor blockers (BN2GR), prokinetics, esophagoprotectors (EFP), ursodeoxycholic acid preparations (UDCA) and other medicines (adsorbents, antibiotics, as- tringents, choleretics, probiotics, antispasmodics and enzymes). A cross-sectional simultaneous study was conducted. RESULTS. 104 patients spent 6476.5 rubles/day on GERD treatment at home: group A – 5184.8 rubles/day; group B – 975.4 rubles/day and group C – 316.3 rubles/day; category V – 51.1% of the cost of all drugs, category E – 27.2% and category N - 21.7%. In class A, category V – 62.1 rubles/day (2.7% of the total cost of Class A drugs), in category E – 3033.1 rubles/day (58.1%) and in category N – 2089.6 rubles/ day. (39.2%). Frequency analysis of drugs from categories V and E showed that the overspent amount of drugs could have been purchased: in the PPIs group – 24 doses of Omeprazole; in the prokinetics group – 13 doses of Itopride; in the antacid group – 20 doses of Almagel®; in the EFP group – 2.4 doses of Alfazox. The cost of the 3 drugs used from the UDCA group was the same. Alginates and BN2GR were accepted by the same name. The same situation was found in category N, with overexpenditure ranging from 1 to 29 doses in the compared groups of secondary drugs. CONCLUSION. The relevance of GERD is due not only to its fairly widespread occurrence, but also to the high financial costs, which do not always take into account financial expediency. Its increase will improve the effectiveness of GERD maintenance therapy.